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In contrast to energetic photons used in conventional radiotherapy, 
the dose delivered in particle therapy using protons and heavier ions 
increases as the particle penetrates the tissue and loses energy 
continuously. The dose therefore increases with increasing tissue 
thickness up to the Bragg peak which occurs near the end of the 
particle's range. Beyond the Bragg peak, the dose drops to zero (for 
protons) or almost zero (for heavier ions) so that particle therapy 
results in enhanced dose delivery to the target tumour and for heavier 
ions a dramatic increase in the ionisation density towards the end of 
the particle’s range. Particles induce elevated levels of DNA damage 
in the tumour tissue cells, ultimately contributing to tumour cell 
death.  
Predictions from biophysical models of interactions of radiation tracks 
with cellular DNA indicate that clustered DNA damage sites, defined 
as two or more lesions formed within one or two helical turns of the 
DNA by passage of a single radiation track, are formed in mammalian 
cells.  These complex DNA damage sites are regarded as a signature of 
ionizing radiation exposure particularly as the likelihood of clustered 
damage sites arising endogenously is low.  For instance it was 
predicted from biophysical modelling that ~30-40% of low LET-induced 
double strand breaks (DSB), a form of clustered damage, are complex 
with the yield increasing to>90% for high LET radiation, consistent 
with the reduced reparability of DSB with increasing ionization density 
of the radiation.  The induction of radiation-induced DNA damage 
sites in mammalian cells has been confirmed experimentally. The 
increased cell killing of tumour cells has to be balanced against the 
increase in normal tissue damage with increasing damage complexity.  
The spatial and temporal aspects of damage distribution will be 
discussed on the ability of ionizing radiation to produce clustered DNA 
damage sites,including DSB, against a plethora of endogenous damage 
induced and that the complexity of the clusters increases with 
ionization density of the radiation.  It is these clustered damage sites 
which lead to the biological effects of ionizing radiation even for a 
low fluence of particle tracks. With particle radiation it is also 
important to consider not only delta-rays which may cause clustered 
damaged sites and may be highly mutagenic but the non-random 
spatial distribution of DSB which may lead to deletions. 
In this overview I will concentrate on the molecular aspects of the 
variation of the complexity of DNA damage on radiation quality and 
the challenges this complexity presents the DNA damage repair 
pathways.  Additionally, for heavier ions than protons, I will develop 
the theme of the change in ionisation density towards the end of the 
particle’s range and how this may impact damage complexity repair 
and the oxygen effect.  These considerations lead to increased 
radiobiological effectiveness. 
In summary the aim is to emphasis the link between the spatial 
distribution of energy deposition events related to the track, the 
molecular products formed and the consequence of damage 
complexity contributing to biological effects and to present some of 
the outstanding molecular challenges with particle radiation.   
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Worldwide, there is an increasing interest in carbon ion radiotherapy 
as it allows for highly conformal treatments of deep-seated tumors 
due to the finite range and the in-verted depth dose profile (Bragg-
curve) of charged particles. In addition, the linear energy transfer 
(LET) is higher in the Bragg-peak region as compared to the beam 
entrance region (plateau), which increases the relative biological 
effectiveness (RBE) towards the distal edge of the depth dose curve. 
The degree of conformality of charged particles is further enhanced 
by introducing active scanning techniques, which allow dose 
conformation not only at the distal but also at the proximal edge of 
the tumor for each field. Clinical trials have been performed in 
Germany and Japan, demonstrating safety and effectiveness of carbon 
ion radiotherapy for a variety of tumors, however a definitive 
confirmation that the use of carbon ions is superior to protons is still 
missing. Hence carbon ion therapy is presently still considered as a 
promising but not completely validated experimental clinical strategy. 
From the radiobiological point of view, a central demand is the fact 
that treatment planning for carbon ions is performed in terms of RBE-
weighted rather than absorbed dose. As the depth modulation for 
active techniques is varying throughout the complete radiation field, 
RBEs have to be calculated locally at each beam spot. The RBE is a 
complex quantity, which depends on physical parameters such as 
dose, LET and particle type as well as on biological properties like the 
tissue type and the biological endpoint. To consider the RBE in 
treatment planning, bio-mathematical models are required. The 
predictions of the RBE by these models, however, are associated with 
significant uncertainties, and moreover are difficult to verify in 
patients.  
As the intention of radiotherapy to achieve complication free tumor 
cure can only be attained when tumor control probability and the risk 
of morbitity are balanced, detailed information about the impact of 
high-LET radiation on both, tumor and normal tissues, is of 
outstanding importance. For normal tissues, there exist a presently 
not fully understood relationship between fractionation, spatial dose 
distribution and the clinical outcome of radiation therapy. For tumors 
the questions whether high-LET irradition can overcome radiation 
resistance against conventional radiation strategies and which 
patients will benefit are most challanging. Ongoing clinical trials 
should therefore be accompanied by pre-clinical studies, which allow 
benchmarking of RBE-models for tumors and normal tissues. Beside 
RBE-models, these studies may also improve the understanding of the 
underlying mechanisms of the radiation damage and can help to assess 
the differential effects of high-LET treatments between tumor- and 
normal tissues.  
In the presentation we aim to summarize the present status of clinical 
particle radiobiology addressing the relative biological effectiveness 
(RBE) and its dependencies on physical and biolological factors; show 
examples how RBEs for normal tissues and tumors are determined and 
discuss some possible underlying mechanisms possessing clinical 
relevance.  
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Radiotherapy is a common therapeutic strategy to cure cancer. The 
introduction of high-energy photons using electron linear accelerators 
has been instrumental in delivering higher doses to deep-seated 
tumours, while reducing the doses absorbed by the surrounding 
healthy tissues. Charged particle beams of protons and carbon ions 
have a much more favourable dose-depth distribution than X-rays and 
indeed protons and carbon ions are becoming widely used in 
radiotherapy, especially for paediatric patients.  
New radiation modalities are certainly increasing local tumor control, 
but there is a potential for an increase in secondary cancers.The issue 
is now becoming of utmost importance, because the number of cancer 
survivors is rapidly increasing (over 10 millions in US) and the age of 
treatment decreasing. Thanks to the advanced treatment modalities, 
about 80% of children and adolescents treated for cancer become 
long-term survivors, but roughly 40% of them develop therapy-related 
morbidity. In USA, several hospitals are opening centers devoted 
exclusively to cancer survivors, and the NCI is supporting the 
Radiogenomics Consortium to study genetic predictors of late effects. 
EU also funded a dedicated study in the field within the 7thFP.   
Mechanisms of therapy-related cancers are similar to those of sporadic 
tumorigenesis, but the carcinogenic potential of low doses of X-rays is 
not completely understood, and the uncertainty is much higher for 
cancer induced by charged particles. However, recent results suggest 
that the reduced integral dose in particle therapy may eventually 
largely decrease the risk of secondary cancer compared to any photon 
treatment. It should also be considered that the additional dose to the 
patient caused by concomitant diagnostic radiology, especially 
computed tomography, can be comparable to that caused by leakage 
radiation or neutrons during the treatment. Novel technological 
improvements may reduce the secondary dose in therapy, whilst 
research in genetic susceptibility should help identifying biomarkers of 
long-term risk in cancer survivor. 
 
 
 
 
 
 
